Antibacterial Nanoparticles Therapeutic (ANT) Study

Summary (Newest Update)

Background The Walter Reed Army Institute of Research (WRAIR), specifically the Bacterial Diseases Branch (BDB), is seeking to conduct a study aimed at testing innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs) against combat-relevant multi-drug resistant (MDR) strains of Pseudomonas aeruginosa. This bacterial pathogen is known to cause hard-to-treat and potentially deadly infections in service members following battlefield injuries. The study aims to introduce novel therapeutics into military healthcare to effectively combat MDR P. aeruginosa. The University of Notre Dame, which holds a patent for this unique technology awarded in 2024 (US-12161725-B2), is collaborating on this initiative. The government anticipates that these collaborative efforts will facilitate FDA approval of this innovative therapy, ultimately leading to reduced morbidity and mortality rates, enhanced operational readiness, advancements in combat medicine, and significant contributions to biosecurity initiatives and civilian health improvements. Work Details The contractor shall provide a non-personal Research and Development effort that includes qualified research personnel, appropriate laboratory facilities, and all necessary laboratory and research-related materials and supplies. The study will consist of three milestones: 1) Production of SilverGold Nanoparticles conjugated to antimicrobial peptide/polymer for testing against P. aeruginosa biofilms; 2) Testing the efficacy of these nanoparticles against P. aeruginosa in a pre-clinical model using Galleria mellonella; 3) Evaluation of the treatment in animal models including mice and swine for chronic wound infections. Each milestone requires specific deliverables such as batches of nanoparticle stock, quality control certificates, and comprehensive documentation on the fundamental properties and effectiveness of the nanoparticles against specified reference strains. Period of Performance The contract will be performed over a period spanning approximately 36 months, divided into three milestones with specific timelines: Milestone One (Months 0-9), Milestone Two (Months 10-18), Milestone Three (Months 19-36). Place of Performance Contractor Facility